Navigation Links
Indevus Announces Presentation of Pagoclone Data at 47th Annual New,Clinical Drug Evaluation Unit Meeting

placebo, demonstrated continued improvement, achieving approximately a 20 point mean decrease over the five month period.

Pagoclone was shown to be safe and well-tolerated. There were no serious adverse events associated with pagoclone. The most commonly reported side effects associated with pagoclone were headache (12.5% for pagoclone and 6.8% for placebo) and fatigue (8% for pagoclone and 0% for placebo). As with all prior trials for pagoclone, reports of somnolence and sedation were similar between pagoclone and placebo. Additionally, pagoclone exerted its clinical effect on patients without disrupting the naturalness of their speech as assessed by the SNS, a validated 9-point scale.

Pagoclone has continued to demonstrate a very favorable safety profile during the open label phase.

About Stuttering

Nearly 3 million Americans, or as much as 1% of the population, are afflicted with persistent stuttering, with approximately 4 times as many males being affected by the condition as females. Stuttering is a DSM-IV-TR Axis I disorder and is characterized by symptoms in which the flow of speech is disrupted by prolongations, repetitions, and blocks of sounds, syllables, words or phrases. The exact cause of stuttering is unknown; however, emerging evidence has shown that this disorder is associated with abnormalities in brain areas related to speech motor control. Stuttering most often begins in early childhood. It often persists into adulthood and this form is classified as persistent developmental stuttering. Given the importance of communication in daily life, stuttering impairs an individual's academic, social and occupational functioning. No medication is FDA approved for stuttering and the most commonly utilized treatment is speech therapy.

About pagoclone

Pagoclone is a novel, non-benzodiazepine, GABA-A selective receptor modulator. It is part of a new chemical class of agents and lacks many of the common benzodiazepine si
'"/>




Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Indevus Reports Positive Data From Phase III NEBIDO Trial
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
(Date:7/24/2014)... WARSAW, Ind., July 24, 2014 Zimmer Holdings, ... for the quarter ended June 30, 2014.  The Company ... increase of 1.2% reported and 0.9% constant currency over ... for the quarter were $1.03 reported and $1.49 adjusted, ... period. "The second quarter was marked ...
(Date:7/24/2014)... , July 24, 2014 ... today announced that it has been selected ... non-profit organization with membership representation from 19 ... subscription-based platform that will transform the way ... clinical trials. TransCelerate BioPharma Inc. is dedicated ...
(Date:7/23/2014)... -- Varian Medical Systems (NYSE: VAR ) today ... in the third quarter of fiscal year 2014.  Net ... share due to an approximately $8 million impairment charge ... in Augmenix, a privately-held company developing minimally invasive hydrogels ... the third quarter of fiscal year 2014, up 3 ...
Breaking Medicine Technology:Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 2Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 3Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 4Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 5Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 6Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 7Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 8Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 9Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 10Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 11Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 12Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 13Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 14Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 15Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 16Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 17Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 18Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 19Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 20Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 21Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 22Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 23Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 24TransCelerate Selects Cognizant to Develop a Clinical Trials Collaboration Platform 2TransCelerate Selects Cognizant to Develop a Clinical Trials Collaboration Platform 3TransCelerate Selects Cognizant to Develop a Clinical Trials Collaboration Platform 4TransCelerate Selects Cognizant to Develop a Clinical Trials Collaboration Platform 5Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2014 2Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2014 3Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2014 4Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2014 5Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2014 6Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2014 7Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2014 8Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2014 9
... NDA for Ondansetron Orally Dissolving Film StripBioAlliance to Resubmit ... Pharmaceuticals, the proprietary products division of a wholly owned ... PRX ), today provides an update on two of ... Strip On April 7, 2009, Strativa submitted a New ...
... April 7 Scientists at Schepens Eye Research Institute ... is essential to the health of blood vessels in ... dysfunction. These findings, published in the April 2 issue ... the prevention and treatment of diseases such as diabetic ...
Cached Medicine Technology:Strativa Pharmaceuticals Provides Product Pipeline Update 2Strativa Pharmaceuticals Provides Product Pipeline Update 3Strativa Pharmaceuticals Provides Product Pipeline Update 4Scientists Discover a Role for the Growth Factor TGF-beta in Maintaining Health of Retinal Blood Vessels 2Scientists Discover a Role for the Growth Factor TGF-beta in Maintaining Health of Retinal Blood Vessels 3
(Date:7/24/2014)... Texas Physical Therapy Specialists ’ ... installation of the AlterG Anti-Gravity Treadmill , a ... to continue training stress-free while recovering from injury. , ... July 2014, uses technology created by NASA to enable ... 80% of the weight normally included in these activities. ...
(Date:7/24/2014)... (PRWEB) July 24, 2014 ... represents a rapidly expanding sector in the in-vitro ... specimen collection devices, new detection technologies, computers, and ... sensitivity, versatility, and speed. In addition to disease ... its benefits in patient stratification, drug regimen selection, ...
(Date:7/24/2014)... ReNewLifeCleansing.com was inspired by ReNew Life ... While waging her battle with poor health, she discovered ... her recovery. She became an expert on cleansing, detoxification, ... minerals, and other ingredients derived from nature help support ... waste and toxins for better overall health. , “Lately, ...
(Date:7/24/2014)... Skin management experts at FACE Skincare Medical Wellness ... the Geneo™ 3-in-1 Super Facial, specifically designed to increase ... large pores, leaving skin looking radiant. FACE is one ... treatment from Israel, and the first and only ... treatment. , This innovative treatment uses the unique ...
(Date:7/24/2014)... Crawford Technologies today announced the ... with AIIM, focusing on global trends in high-volume ... the survey indicated that even though organizations stated ... customer service, legal and regulatory compliance and historical ... exact facsimiles of these documents. , The survey ...
Breaking Medicine News(10 mins):Health News:Texas Physical Therapy Specialists Helps Patients Recover With AlterG Anti-Gravity Treadmill 2Health News:Increasing Molecular Level Understanding of Disease State & Metabolism Drives the Molecular Diagnostics Market, According to New Report by Global Industry Analysts, Inc. 2Health News:Increasing Molecular Level Understanding of Disease State & Metabolism Drives the Molecular Diagnostics Market, According to New Report by Global Industry Analysts, Inc. 3Health News:Increasing Molecular Level Understanding of Disease State & Metabolism Drives the Molecular Diagnostics Market, According to New Report by Global Industry Analysts, Inc. 4Health News:ReNew Life Launches New Educational Cleansing & Detox Website—ReNewLifeCleansing.com 2Health News:FACE Skincare Medical Wellness Debuts Exclusive 3-in-1 Facial Treatment in Michigan 2Health News:AIIM Research Shows 56% of Organizations Not Utilizing Digital Archiving Technology 2Health News:AIIM Research Shows 56% of Organizations Not Utilizing Digital Archiving Technology 3Health News:AIIM Research Shows 56% of Organizations Not Utilizing Digital Archiving Technology 4
... transplanted almost half of face taken from a brain dead donor ... from the lips, nose and chin was taken and transplanted to ... ,Doctors have clarified that the face the woman ... not resemble the donor’s face. ,If accepted the real ...
... international team of researchers has revealed that the inhalers ... chances of an attack.// Mathematical modeling techniques have been ... an asthma attack is likely to take place. The ... study. ,Silverman, professor of child health in the ...
... to make improvements in the services it provides children. ... ill should not be compelled to visit // hospitals for ... Department of Health which insists that individual needs must be ... at home like nurse led services. , It should ...
... been paying lesser attention to programs with regard to ... social development. The Social Development Research Group of the ... almost 600 students which revealed that tackling anti-social tendencies ... contributes towards better academic performance. ,The progress reported ...
... The application of anti-microbial coating over artificial implants such ... to reduce the infection rates following surgery. // This ... the health care cost and an improvement in the ... surgery, the implantable devices are prone for infection. In ...
... is all praise for the healthcare facilities available in India ... The surgery at the Ramaiah Memorial Hospital has cured her ... as she was unable to get the treatment on the ... her 5,000 pounds. The NHS in the UK has come ...
Cached Medicine News:Health News:Asthma Attacks May Be Triggered By Inhalers 2Health News:Anti-Microbial Coating For Use Over Biomedical Devices Developed 2Health News:Indian Healthcare Facilities Come In For Praise 2
The Buechel-pappas™ Total Ankle Replacement is a time-tested system which is the result of more than twenty years of development, clinical investigation, and use. The components have been avai...
The Assistant Free Self-Retaining Hip Surgery Retractor System is used for hip arthroplasty and hip fracture surgery....
The Endotrac™ System includes an Obturator, Slotted Cannula, Synovial Elevator, Ligament Probe, Ligament Rasp, Blade Handle, two Retractors and sterilizable tray. The Endotrac&trade....
Low-profile hand-held instruments....
Medicine Products: